Puma Biotechnology Inc (NYSE:PBYI) SVP Richard Paul Bryce sold 15,000 shares of Puma Biotechnology stock in a transaction on Friday, September 29th. The stock was sold at an average price of $120.00, for a total transaction of $1,800,000.00. Following the transaction, the senior vice president now owns 42,239 shares in the company, valued at approximately $5,068,680. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Richard Paul Bryce also recently made the following trade(s):

  • On Thursday, September 7th, Richard Paul Bryce sold 15,000 shares of Puma Biotechnology stock. The stock was sold at an average price of $100.09, for a total transaction of $1,501,350.00.
  • On Thursday, July 20th, Richard Paul Bryce sold 1,998 shares of Puma Biotechnology stock. The stock was sold at an average price of $94.48, for a total transaction of $188,771.04.

Puma Biotechnology Inc (NYSE PBYI) opened at 119.85 on Tuesday. The stock has a 50 day moving average price of $97.20 and a 200 day moving average price of $72.06. The company’s market capitalization is $4.46 billion. Puma Biotechnology Inc has a 52-week low of $28.35 and a 52-week high of $122.25.

Puma Biotechnology (NYSE:PBYI) last announced its quarterly earnings data on Wednesday, August 9th. The biopharmaceutical company reported ($2.10) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.32) by ($0.78). Equities research analysts forecast that Puma Biotechnology Inc will post ($8.67) earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: “Puma Biotechnology Inc (PBYI) SVP Richard Paul Bryce Sells 15,000 Shares of Stock” was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece on another publication, it was copied illegally and republished in violation of United States and international copyright & trademark legislation. The legal version of this piece can be viewed at https://www.thecerbatgem.com/2017/10/03/puma-biotechnology-inc-pbyi-svp-richard-paul-bryce-sells-15000-shares-of-stock.html.

Several research analysts recently issued reports on the company. Credit Suisse Group raised their target price on Puma Biotechnology from $118.00 to $136.00 and gave the stock an “outperform” rating in a research report on Monday, September 11th. J P Morgan Chase & Co reiterated a “buy” rating on shares of Puma Biotechnology in a research report on Tuesday, August 1st. Zacks Investment Research lowered Puma Biotechnology from a “hold” rating to a “sell” rating in a research report on Tuesday, July 11th. Leerink Swann reissued an “outperform” rating and issued a $115.00 price target on shares of Puma Biotechnology in a research note on Monday, July 10th. Finally, Citigroup Inc. reissued a “buy” rating and issued a $105.00 price target on shares of Puma Biotechnology in a research note on Friday, June 30th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $112.70.

Several hedge funds and other institutional investors have recently modified their holdings of PBYI. Paulson & CO. Inc. raised its holdings in Puma Biotechnology by 75.3% during the 2nd quarter. Paulson & CO. Inc. now owns 27,500 shares of the biopharmaceutical company’s stock valued at $2,404,000 after buying an additional 11,810 shares during the last quarter. Ameritas Investment Partners Inc. boosted its position in Puma Biotechnology by 5.9% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,522 shares of the biopharmaceutical company’s stock valued at $220,000 after buying an additional 140 shares during the period. The Manufacturers Life Insurance Company boosted its position in Puma Biotechnology by 2.0% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 22,299 shares of the biopharmaceutical company’s stock valued at $1,950,000 after buying an additional 437 shares during the period. Cubist Systematic Strategies LLC purchased a new stake in Puma Biotechnology during the 2nd quarter valued at $146,000. Finally, Janus Henderson Group PLC bought a new stake in Puma Biotechnology in the 2nd quarter worth $162,302,000. 80.98% of the stock is currently owned by institutional investors.

About Puma Biotechnology

Puma Biotechnology, Inc is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357.

Insider Buying and Selling by Quarter for Puma Biotechnology (NYSE:PBYI)

Receive News & Stock Ratings for Puma Biotechnology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology Inc and related stocks with our FREE daily email newsletter.